Manufacturing: Page 9
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
FDA delays testing of Inovio's coronavirus vaccine
The FDA has suspended the planned start of a late-stage trial of Inovio's experimental shot, dealing another setback to one of the most advanced DNA-based vaccine programs in development.
By Jonathan Gardner • Sept. 28, 2020 -
Permission granted by BioNTech SE
Drugmakers push forward on large-scale production of coronavirus vaccines
HHS Secretary Alex Azar said six vaccine developers involved with Operation Warp Speed had begun commercial manufacturing of their experimental shots.
By Ned Pagliarulo • Sept. 24, 2020 -
AstraZeneca turns to Samsung Biologics to help fuel Asia drugs push
The British drugmaker struck a manufacturing deal with Samsung to expand its ability to supply drugs to the Asia Pacific region, an area that's been key to its recent growth.
By Kristin Jensen • Sept. 24, 2020 -
Permission granted by BioNTech SE
BioNTech to buy Novartis manufacturing plant to bolster vaccine supply
The site, set to be one of the largest mRNA manufacturing plants in Europe, will help BioNTech and partner Pfizer make 750 million more doses of their coronavirus shot per year.
By Kristin Jensen • Sept. 17, 2020 -
Permission granted by Takeda Pharmaceutical
Takeda adds to cell therapy push with new manufacturing site
The Japanese drugmaker has made cell therapy a focus, advancing three experimental cancer treatments into clinical testing with plans for two more.
By Ned Pagliarulo • Sept. 15, 2020 -
Courtesy of Novavax, Australian Broadcasting Corporation
Novavax boosts coronavirus vaccine manufacturing capacity as key trial nears
The Serum Institute of India, a go-to partner for coronavirus vaccine makers, will help Novavax boost capacity to levels matching its larger rivals.
By Jonathan Gardner • Sept. 15, 2020 -
Catalent to invest $130M in gene therapy plant near Baltimore airport
The contract manufacturer is riding a boom in demand for both its gene therapy and vaccine manufacturing services.
By Kristin Jensen • Sept. 10, 2020 -
Getty / Edited by BioPharma Dive
FDA wants more details on Sarepta gene therapy, potentially delaying final test
A new request from the regulator could tighten the race between Sarepta and Pfizer to prove out a gene therapy for Duchenne muscular dystrophy.
By Ben Fidler • Sept. 10, 2020 -
Pfizer, BioNTech in final talks to supply EU with coronavirus vaccine
The companies, which are among the furthest along in testing, would deliver up to 300 million doses of their shot to EU countries under a proposed deal.
By Kristin Jensen • Sept. 9, 2020 -
FDA scolds Mylan for 'repeated' manufacturing problems
Though it once had a glimmering manufacturing record, Mylan now finds itself in the crosshairs of the FDA. The agency is advising the company to quickly and comprehensively assess its global operations.
By Jacob Bell • Updated Sept. 4, 2020 -
Catalent, seeing rising demand, to expand Indiana production plant
The planned $50 million infusion is the third investment in Catalent's Bloomington facility in two years, reflecting the need for vial filling for biologic drugs and vaccines.
By Kristin Jensen • Sept. 3, 2020 -
Courtesy of CanSino Biologics
CanSino, Canada abandon plans for a coronavirus vaccine trial
Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study.
By Kristin Jensen • Aug. 27, 2020 -
AstraZeneca broadens coronavirus vaccine manufacturing deal with Catalent
Catalent, which is already helping the British pharma make its vaccine, will now add key services from a Maryland gene therapy plant.
By Kristin Jensen • Aug. 26, 2020 -
Moderna joins other vaccine leaders in European supply talks
The deal would designate up to 160 million doses of Moderna's shot for the European Union, which has worked aggressively of late to bolster its supply.
By Jonathan Gardner • Aug. 24, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
CureVac in talks to supply EU with coronavirus vaccine
A deal being negotiated would provide EU countries with 225 million doses of CureVac's experimental shot, which relies on similar technology as those developed by Moderna and BioNTech.
By Kristin Jensen • Aug. 20, 2020 -
Regeneron enlists Roche to boost production of COVID-19 antibody drug
Together, the companies expect they can make more than three times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own.
By Kristin Jensen • Aug. 19, 2020 -
Europe, trailing US, UK, reaches first coronavirus vaccine deal
Both the U.S. and U.K. have aggressively signed preorder deals with vaccine developers. An agreement with AstraZeneca is the EU's first.
By Ned Pagliarulo • Aug. 14, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
Argentina, Mexico line up to produce AstraZeneca, Oxford coronavirus vaccine
The manufacturing deal could help supply Latin America with Oxford's shot, which is one of the most advanced in clinical testing.
By Kristin Jensen • Aug. 13, 2020 -
US puts Kodak loan on hold after stock scrutiny
Lawmakers questioned the timing of stock options granted to Kodak executives a day before the planned $765 million loan was announced. An SEC investigation is reportedly underway.
By Ned Pagliarulo • Aug. 10, 2020 -
Permission granted by Gilead Sciences
Pfizer to help Gilead produce COVID-19 drug remdesivir
With supplies of the in-demand drug tight, Gilead has enlisted Pfizer, along with companies across the globe, to churn out millions of treatment courses.
By Ned Pagliarulo • Aug. 7, 2020 -
Trump tries to revamp drug supply chain with latest order
A directive announced by the president would require government agencies to buy certain "essential" drugs from factories in the U.S. How easily such an order would be implemented isn't clear.
By Ben Fidler • Aug. 6, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
India's role in coronavirus vaccine manufacturing grows with new deals
The Serum Institute, one of the world's largest vaccine producers, licensed Novavax's experimental shot, while Wockhardt signed on with the U.K. to help make AstraZeneca's candidate.
By Kristin Jensen • Aug. 6, 2020 -
Courtesy of FujiFilm
US taps camera makers for help manufacturing drugs, vaccines
The Trump administration plans to loan Kodak $765 million to produce drug ingredients, one day after enlisting Fujifilm to help make coronavirus vaccines.
By Ned Pagliarulo • July 28, 2020 -
Retrieved from Sandoz on July 27, 2020
Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing
About a third of the money will come from the Austrian government and be put toward technology used to make the active ingredients in penicillin products.
By Jacob Bell • July 27, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
UK to spend almost $130M more on coronavirus vaccine manufacturing
The investment will upgrade a Cell and Gene Therapy Catapult site so it can manufacture coronavirus vaccines and respond to future pandemics.
By Jacob Bell • July 23, 2020
Previous
